Masaru Takagi1, Yusuke Demizu2, Naoki Hashimoto2, Masayuki Mima2, Kazuki Terashima2, Osamu Fujii2, Dongcun Jin2, Yasue Niwa3, Koichi Morimoto4, Takashi Akagi5, Takashi Daimon6, Ryohei Sasaki7, Yoshio Hishikawa8, Mitsuyuki Abe2, Masao Murakami9, Nobukazu Fuwa2. 1. Department of Radiology, Hyogo Ion Beam Medical Center, Tatsuno, Japan. Electronic address: mtakagidear@gmail.com. 2. Department of Radiology, Hyogo Ion Beam Medical Center, Tatsuno, Japan. 3. Department of Radiology, Hyogo College of Medicine, Nishinomiya, Japan. 4. Division of Otorhinolaryngology-Head and Neck Surgery, Kobe University Graduate School of Medicine, Japan. 5. Department of Radiation Physics, Hyogo Ion Beam Medical Center, Tatsuno, Japan. 6. Department of Biostatistics, Hyogo College of Medicine, Nishinomiya, Japan. 7. Section of Radiation Oncology, Kobe University Graduate School of Medicine, Japan. 8. Department of Radiology, Medipolis Proton Therapy and Research Center, Ibusuki, Japan. 9. Center for Radiation Oncology, Dokkyo Medical University, Shimotsuga-gun, Japan.
Abstract
BACKGROUND AND PURPOSE: The aim of this study was to retrospectively analyse the outcomes of cases of adenoid cystic carcinomas (ACCs) of the head and neck that were treated at a single institution with particle therapy consisting of either protons or carbon ions. METHODS AND MATERIALS: Between February 2002 and March 2012, 80 patients were treated with proton therapy (PT) or carbon ion therapy (CIT) alone. PT and CIT were employed in 40 (50%) patients each, and more than half of the patients received 65.0 GyE in 26 fractions (n=47, 59%). RESULTS: The median duration of follow-up was 38 months (range, 6-115 months). For all patients, the 5-year for overall survival (OS) rate, progression-free survival (PFS) rate, and local control (LC) rate were 63%, 39%, and 75%, respectively. No significant differences between PT and CIT were observed. The 5-year LC rates for T4 and inoperable cases were 66% and 68%, respectively. Twenty-one patients (26%) experienced grade 3 or greater late toxicities, including three patients who developed grade 5 bleeding from nasopharyngeal ulcers. CONCLUSIONS: Particle radiotherapy for ACC achieves favourable LC, and its efficacy in inoperable or T4 cases is promising. There were no significant differences between PT and CIT in terms of OS, PFS and LC.
BACKGROUND AND PURPOSE: The aim of this study was to retrospectively analyse the outcomes of cases of adenoid cystic carcinomas (ACCs) of the head and neck that were treated at a single institution with particle therapy consisting of either protons or carbon ions. METHODS AND MATERIALS: Between February 2002 and March 2012, 80 patients were treated with proton therapy (PT) or carbon ion therapy (CIT) alone. PT and CIT were employed in 40 (50%) patients each, and more than half of the patients received 65.0 GyE in 26 fractions (n=47, 59%). RESULTS: The median duration of follow-up was 38 months (range, 6-115 months). For all patients, the 5-year for overall survival (OS) rate, progression-free survival (PFS) rate, and local control (LC) rate were 63%, 39%, and 75%, respectively. No significant differences between PT and CIT were observed. The 5-year LC rates for T4 and inoperable cases were 66% and 68%, respectively. Twenty-one patients (26%) experienced grade 3 or greater late toxicities, including three patients who developed grade 5 bleeding from nasopharyngeal ulcers. CONCLUSIONS: Particle radiotherapy for ACC achieves favourable LC, and its efficacy in inoperable or T4 cases is promising. There were no significant differences between PT and CIT in terms of OS, PFS and LC.
Authors: Shekhar K Gadkaree; Anuraag S Parikh; Eric Barbarite; Allen L Feng; Justin McCarty; Stacey T Gray; Derrick T Lin Journal: J Neurol Surg B Skull Base Date: 2020-12-04
Authors: Sarah Atallah; Morgane Marc; Antoine Schernberg; Florence Huguet; Isabelle Wagner; Antti Mäkitie; Bertrand Baujat Journal: Cancer Manag Res Date: 2022-06-04 Impact factor: 3.602
Authors: Arnold Pompos; Robert L Foote; Albert C Koong; Quynh Thu Le; Radhe Mohan; Harald Paganetti; Hak Choy Journal: Front Oncol Date: 2022-06-14 Impact factor: 5.738